For BCSM and OCSM, the Fine and Gray competing risk analysis was used, and the following factors were validated (Table 3): older age, poorer differentiation, larger tumor size, triple negative subtype, HER2‐enriched subtype, and absence of surgery for BCSM and older age, larger tumor size, and absence of surgery for OCSM. Here, ERBB2 is linked to neoplasm.